Exagen Q4 GAAP EPS $(0.31) Beats $(0.43) Estimate, Sales $13.77M Beat $11.56M Estimate
Exagen Q4 GAAP EPS $(0.31) Beats $(0.43) Estimate, Sales $13.77M Beat $11.56M Estimate
Exagen第四季度GAAP每股收益美元（0.31）超過預期（0.43美元），銷售額1377萬美元超過預期的1156萬美元
Exagen (NASDAQ:XGN) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.43) by 27.91 percent. This is a 62.65 percent increase over losses of $(0.83) per share from the same period last year. The company reported quarterly sales of $13.77 million which beat the analyst consensus estimate of $11.56 million by 19.07 percent. This is a 7.23 percent increase over sales of $12.84 million the same period last year.
Exagen（納斯達克股票代碼：XGN）公佈的季度虧損爲每股0.31美元，比分析師普遍預期的0.43美元（0.43美元）高出27.91％。與去年同期每股虧損0.83美元（0.83）相比，增長了62.65％。該公司公佈的季度銷售額爲1,377萬美元，比分析師普遍預期的1156萬美元高出19.07％。這比去年同期的1,284萬美元的銷售額增長了7.23％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。